TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+2.99%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$671M
AUM Growth
+$671M
(-2.5%)
Cap. Flow
+$89.1M
Cap. Flow
% of AUM
13.28%
Top 10 Holdings %
Top 10 Hldgs %
38.66%
Holding
127
New
38
Increased
28
Reduced
16
Closed
24
Top Buys
| 1 |
Novo Nordisk
NVO
|
$21.5M |
| 2 |
Evolus
EOLS
|
$20.2M |
| 3 |
BLUE
bluebird bio
BLUE
|
$16.7M |
| 4 |
FLG
Flagstar Financial, Inc.
FLG
|
$14.5M |
| 5 |
Adicet Bio
ACET
|
$11.1M |
Top Sells
| 1 |
AnaptysBio
ANAB
|
$13M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$12M |
| 3 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$8.9M |
| 4 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$6.72M |
| 5 |
Cytokinetics
CYTK
|
$5.04M |
Sector Composition
| 1 | Healthcare | 91.26% |
| 2 | Financials | 6.75% |
| 3 | Real Estate | 0.31% |
| 4 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Capital One
COF
$142B
| $9.62M | 1.43% |
+100,000
| New | +$9.62M |
|
27
CytomX Therapeutics
CTMX
$350M
| $9.2M | 1.37% |
6,093,032
+2,582,587
| +74% | +$3.9M |
|
|
28
Alnylam Pharmaceuticals
ALNY
$58.6B
| $9.01M | 1.34% |
45,000
-60,000
| -57% | -$12M |
|
|
AMRN
29
Amarin Corp
AMRN
$311M
| $8.1M | 1.21% |
+270,000
| New | +$8.1M |
|
30
Bio-Rad Laboratories Class A
BIO
$7.8B
| $7.66M | 1.14% |
16,000
-5,000
| -24% | -$2.4M |
|
|
THRD
31
DELISTED
Third Harmonic Bio
THRD
| $7.42M | 1.11% |
1,800,000
+100,000
| +6% | +$412K |
|
32
Ionis Pharmaceuticals
IONS
$9.64B
| $7.15M | 1.07% |
200,000
| – | – |
|
|
BLPH
33
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $7.05M | 1.05% |
+893,974
| New | +$7.05M |
|
34
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $6.46M | 0.96% |
600,000
| – | – |
|
35
Nkarta
NKTX
$149M
| $6.34M | 0.94% |
1,785,829
-84,171
| -5% | -$299K |
|
36
Comerica
CMA
$9B
| $5.8M | 0.86% |
+133,525
| New | +$5.8M |
|
37
Quince Therapeutics
QNCX
$86.5M
| $5.65M | 0.84% |
+3,620,000
| New | +$5.65M |
|
|
ENZ
38
DELISTED
Enzo Biochem, Inc.
ENZ
| $5.59M | 0.83% |
+2,300,000
| New | +$5.59M |
|
39
Cullinan Oncology
CGEM
$456M
| $5.12M | 0.76% |
500,000
-309,231
| -38% | -$3.16M |
|
|
TCRR
40
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $5.1M | 0.76% |
3,399,745
+660,798
| +24% | +$991K |
|
|
GNFT
41
Genfit
GNFT
$198M
| $4.97M | 0.74% |
1,212,515
+14,993
| +1% | +$61.5K |
|
|
LENZ
42
LENZ Therapeutics
LENZ
$1.12B
| $4.97M | 0.74% |
289,781
+132,638
| +84% | +$2.27M |
|
|
IMGN
43
DELISTED
Immunogen Inc
IMGN
| $4.9M | 0.73% |
1,274,853
| – | – |
|
44
Dianthus Therapeutics
DNTH
$781M
| $4.81M | 0.72% |
+378,125
| New | +$4.81M |
|
45
Citigroup
C
$175B
| $4.69M | 0.7% |
+100,000
| New | +$4.69M |
|
46
Fate Therapeutics
FATE
$115M
| $3.99M | 0.59% |
+700,000
| New | +$3.99M |
|
|
FRC
47
DELISTED
First Republic Bank
FRC
| $3.9M | 0.58% |
+278,759
| New | +$3.9M |
|
48
Enanta Pharmaceuticals
ENTA
$189M
| $3.64M | 0.54% |
90,000
-110,000
| -55% | -$4.45M |
|
49
Galapagos
GLPG
$2.06B
| $3.46M | 0.52% |
89,650
-25,300
| -22% | -$978K |
|
50
Atea Pharmaceuticals
AVIR
$275M
| $3.36M | 0.5% |
+1,002,582
| New | +$3.36M |
|